Fig. 1: ARIH1 accumulates after treatment of 4T1 tumor models with a combination of cisplatin and anti-PD-L1 antibody.

a, b Tumor growth curves and tumor weights upon subcutaneous injection of 5 × 10⁵ 4T1 cells into female BALB/c mice (6–8 week old) treated with vehicle, cisplatin alone, anti-PD-L1 alone and cisplatin+anti-PD-L1. n = 6 mice/group. Data represent means ± SEM. a ^**P < 0.01 (P = 0.0052), ^****P < 0.0001. b ^**P < 0.01 (P = 0.0014), ^***P < 0.001 (P = 0.0007), ^****P < 0.0001. c The survival curves of tumor bearing mice with indicated treatments. n = 7 mice/group. Log-rank test, ^*P < 0.05 (P = 0.0351), ^**P < 0.01 (P = 0.0023). d, e. Representative images of tumor CD8 and GzmB IHC staining of the mice as in (a). The percent of each expression pattern was quantified (e). Scale bar, 60 μm. n = 6 mice/group. Data represent means ± SEM, ^***P < 0.001 (P = 0.0002), ^****P < 0.0001. f Representative ARIH1 IHC staining for tumors of the mice as in (a). The percent of expression pattern was quantified. Scale bar, 60 μm. n = 6 mice/group. Data represent means ± SEM, ^*P < 0.05 (P = 0.0233). g Immunoblots analysis of the ARIH1 protein levels in the indicated tumor lysates of mice as in (a). h–j Tumor growth, final tumor image and tumor weights of Ctrl-KD and Arih1-KD 4T1 cells in female BALB/c mice (n = 7 per group, 6–8 week old) with indicated treatments. Data represent means ± SEM. h ^**P < 0.01, ^****P < 0.0001. j ^*P < 0.05, ^****P < 0.0001, ns, not significant. Data shown in a and h are representative of three independent experiments. For a, h data, Two-way ANOVA test. For b, e, j data, One-way ANOVA test. For f data, Two-tailed t-test. Source data are provided as a Source Data file.